Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has entered into a securities purchase agreement with institutional and accredited investors to raise approximately $2.61 million in gross proceeds. The transaction involves the sale of 5,208,333 American Depositary Shares (ADSs) at $0.48 per ADS, along with accompanying Series A and Series B warrants. Additionally, the company executed a warrant inducement agreement with an existing investor. The closing is expected on or about April 27, 2026, subject to customary conditions.
The company stated that the proceeds will be used to support the expansion of its contract development and manufacturing organization (CDMO) platform, advance customer programs, and continue investment in its immunotherapy pipeline. This capital infusion is crucial for Scinai as it seeks to scale its manufacturing capabilities and progress its therapeutic candidates.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., a CDMO that provides development and manufacturing services to other biotechnology and pharmaceutical companies.
The private placement and warrant inducement come at a time when biotech firms are increasingly seeking funding to advance their pipelines and expand manufacturing capabilities. For Scinai, the funds will enable it to better serve its CDMO clients and potentially accelerate the development of its own immunology candidates.
Investors and industry observers will be watching how Scinai utilizes these proceeds to strengthen its position in the competitive biopharmaceutical landscape. The company's ability to execute on its growth plans could have implications for both its shareholders and the broader immunotherapy sector.
For more information, the full press release is available at https://ibn.fm/6Vw4O, and the latest news on SCNI can be found at https://ibn.fm/SCNI.
